|
KaloBios commences KB003 Phase 2 trial in severe asthma
News-Medical.net KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma … |
View full post on asthma – Google News